An Expanded Access Program for AM0010 (Pegilodecakin)

* Patient is NOT eligible for other AM0010 clinical trials currently open in the region * Patient is in urgent need of therapy who fail to meet eligibility criteria for other clinical trials related to AM0010 (PEG-IL-10) can be considered for enrollment into this Expanded Access Program. * Patient has advanced cancer in indications where preliminary anti-tumor efficacy of AM0010 has been demonstrated or where AM0010 mediated immune activation is likely to benefit the patient. * Patient has failed or progressed on standard of care (SOC) systemic therapy * Patient is refusing SOC therapy